Atopic Dermatitis Topical Solution
Celfex AB is a co-development SPV with leading partners combining their capability to address unmet needs. We aspire to help children and adults suffering from Eczema (Atopic Dermatitis) — a first-of-its-kind stable formulation of Fexofenadine to be administered topically. Ready for Phase 2 study.
Strategic Partnership & Investment InquiriesOur Ambition
A clinically approved solution to market by 2028 — a co-developed, orchestrated and holistic approach that considers all stakeholders, including care givers (parents) and patients, both adults and children.
Leading Intellectual Property
The drug designer is partnered in the journey and aligned to success-based clinical outcomes.
Clinical Development Plan
Practical and cost-effective. Holistic thinking, leveraging partnerships with aligned incentives.
Focus on Time to Value
Value to patients and value to investors. Clinical pathways driving fast value inflection and optionality for both OTC and prescription.
Future Roadmap
Reasonable claims to begin with — recognizing the multi-indication potential of this platform.
The Untapped Potential of Fexofenadine
An unmet need exists for cost-effective and tolerable treatment of Atopic Dermatitis. Our patent-granted topical formulation of Fexofenadine targets multiple pathways involved in the disease, offering a novel multi-action approach to treating eczema. Compared with oral administration today, Celfex applies the active ingredient where it is needed, thereby reducing possible liver toxicity.
Learn more about our science →A Large, Under-Served Market
Atopic dermatitis (eczema) affects millions worldwide, with the greatest unmet need among children. Celfex targets the mild-to-moderate segment with a cost-effective, once-daily solution.
Projected atopic dermatitis market by 2031
Of children affected by atopic dermatitis worldwide
Of eczema patients are children — and, indirectly, their guardians (parents), our priority population
Compliance-friendly topical lotion, OTC & prescription
Market figures based on independent valuation (DelveInsight). Celfex addresses an estimated 8.5% of the mild-to-moderate segment.
Our Clinical Plan
Celfex is built on a known molecule with an established safety profile. With Phase 1 complete, we are advancing into a Phase 2 bridge study.
Preclinical & Phase 1
Proprietary once-daily formulation meeting stability standards. Phase 1 showed the lotion was well tolerated with no adverse reactions, positive sensorial perception, and a promising once-a-day pharmacokinetic profile. Patent US11833141 granted.
Phase 2a/2b Bridge
Evaluating safety and efficacy in children with moderate-to-severe atopic dermatitis, with several regional CRO partners collaborating. Target study start Q4 2026 and completion Q2 2027. Strategic collaborators welcome.
Phase 3 & Product Release
Planning for parallel studies, including FDA engagement, following Phase 2 success. Evaluating OTC and prescription versions based on target-market needs. Target: 2028.
Latest News
Celfex AB opens CRO partner discussions for Phase 2
Celfex AB opens CRO partner discussions and plans for its Phase 2 clinical study, with partner selection and announcement planned for BIO 2026.
Celfex AB established as SPV, enters sub-licensing agreement with OrchestratePharma GmbH
Through Celfex AB, Swiss-based OrchestratePharma enters into a co-development partnership with Cellix Bio and other strategic CRO partners.
Invest or Partner With Us
We are seeking strategic investors and clinical partners who share our vision of bringing innovative, accessible dermatology treatments to patients worldwide. We also welcome enquiries about participation in our clinical development programme.